



ASX ANNOUNCEMENT

Lumos successfully completes institutional component of Entitlement Offer

MELBOURNE, Australia (8 June 2022) – Lumos Diagnostics (ASX: LDX), (**Lumos** or the **Company**) a leader in rapid point-of-care (**POC**) diagnostic technologies, is pleased to announce the successful completion of the institutional component of its recently announced fully underwritten A\$11.2 million equity raising, via a 1 for 2.55 pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer**), with a total of approximately A\$8.0 million raised from institutional and sophisticated investors. Participants will also receive 1 free option for every 1 share subscribed for under the Entitlement Offer with an exercise price of A\$0.30 per option and an expiry date of 30 November 2022 (**Option**). The funds were raised through the institutional component of the Entitlement Offer (**Institutional Entitlement Offer**), which opened on Monday, 6 June 2022 and closed on Tuesday, 7 June 2022.

The retail component of the Entitlement Offer (**Retail Entitlement Offer**) will raise approximately a further A\$3.2 million. The Retail Entitlement Offer is expected to open at 9.00am (AEST) on Friday, 10 June 2022 and close at 5.00pm (AEST) on Thursday, 23 June 2022.

Shares in Lumos are expected to recommence trading on an ex-entitlement basis from market open today. The Entitlement Offer is fully underwritten by the Joint Lead Managers, Wilsons Corporate Finance Limited and Bell Potter Securities Limited.

Completion of the Institutional Entitlement Offer

The Institutional Entitlement Offer to raise approximately A\$8.0 million via the issue of 41.9 million new shares was well supported by eligible institutional shareholders. Planet Innovation, Lumos' largest shareholder took up their full Entitlement under the Institutional Entitlement Offer and acted as partial sub-underwriter to the Entitlement Offer. The shortfall under the Institutional Entitlement Offer also attracted very strong demand with broad support from both existing shareholders and new investors.

New shares will be issued at a fixed price of A\$0.19 per share and will rank equally with existing shares from allotment. New shares issued under the Institutional Entitlement Offer are expected to settle on Friday, 10 June 2022. Commencement of normal trading on the ASX of these new shares is expected to occur on Wednesday, 15 June 2022.

The Company intends to use the proceeds of the Entitlement Offer (excluding any funds raised on exercise of Options), together with its existing cash reserves as of 30 April 2022, as follows:

- progress the current applications for regulatory clearances of FebriDx[®], ViraDx[™] and CoviDx[™];
- initiate the commercial launch of these products in the relevant jurisdictions, if applications for regulatory clearances are successful;
- support the development of Lumos' contract development and manufacturing business; and
- for working capital purposes.

Commencement of Retail Entitlement Offer

The Retail Entitlement Offer to raise approximately A\$3.2 million via the issue of ~17.2 million new shares is expected to open at 9.00am (AEST) on Friday, 10 June 2022 and close at 5.00pm (AEST) on Thursday, 23 June 2022. Eligible Retail Shareholders (defined below) who hold shares in Lumos as at 7.00pm (AEST) on the record date of Wednesday, 8 June 2022 will be invited to participate in the Retail Entitlement Offer at the same offer price and offer ratio as the participants in the Institutional Entitlement Offer, being A\$0.19 offer price and an offer ratio of 1 for 2.55.

Eligible Retail Shareholders wishing to participate in the Retail Entitlement Offer should carefully read the Prospectus and accompanying personalised entitlement and acceptance form, which are expected to be dispatched to Eligible Retail Shareholders on Friday, 10 June 2022. The Prospectus will provide details of how to participate in the Retail Entitlement Offer. A copy of the Prospectus was lodged with the ASX on Monday, 10 June 2022.

The Retail Entitlement Offer will be made to all shareholders who:

- were registered as the holder of Shares as at 7.00pm (Sydney time) on the Record Date (being 7:00pm on Wednesday, 8 June 2022);
- have a registered address in Australia or New Zealand;
- are not in the United States nor acting for the account or benefit of a person in the United States or elsewhere outside Australia and New Zealand; and
- do not hold Shares on behalf of another person who resides outside Australia or New Zealand (unless they hold Shares in another eligible capacity),

being, an Eligible Retail Shareholder.

Any Retail Shareholders who are not Eligible Retail Shareholders are 'Ineligible Retail Shareholders'. The Company reserves the right to determine whether a Shareholder is an Eligible Retail Shareholder or an Ineligible Retail Shareholder.

Key dates for the Entitlement Offer

Event	Date
Announcement of completion of Institutional Entitlement Offer, trading halt lifted and existing Shares re-commence trading on an ex-entitlement basis	Wednesday, 8 June 2022
Record date for the Entitlement Offer (7:00 pm Sydney time)	Wednesday, 8 June 2022
Retail Entitlement Offer opens	Friday, 10 June 2022
Prospectus and Entitlement and Acceptance Form distributed to eligible shareholders	Friday, 10 June 2022
Settlement of the Institutional Entitlement Offer	Friday, 10 June 2022
Issue of New Shares under the Institutional Entitlement Offer	Tuesday, 14 June 2022
Commencement of trading of New Shares issued under the Institutional Entitlement Offer	Wednesday, 15 June 2022
Retail Entitlement Offer closes (5:00 pm Sydney time)	Thursday, 23 June 2022
Issue of New Shares under the Retail Entitlement Offer, and Options under the Entitlement Offer	Thursday, 30 June 2022
Commencement of trading of New Shares under the Retail Entitlement Offer and Options ¹	Friday, 1 July 2022
Dispatch of holding statements for New Shares under the Retail Entitlement Offer, and Options	Monday, 4 July 2022

Subject to the requirements of the Corporations Act, the ASX Listing Rules and any other applicable laws, Lumos and the Joint Lead Managers reserve the right to amend this timetable at any time, including extending the Retail Entitlement Offer Period or accepting late applications, either generally or in particular cases, without notice.

Additional information

Lumos intends to provide an online presentation to Eligible Retail Shareholders during the period that the Retail Entitlement Offer is open (i.e., Friday, 10 June 2022 to 5:00pm on Thursday, 23 June 2022). Eligible Retail Shareholders who wish to be notified of the online presentation need to register on Lumos' 'Subscribe to investor news' facility on Lumos' website which can be accessed using the following link: <https://lumosdiagnostics.com/subscribe-to-investor-news/>

This announcement was approved by the Lumos Disclosure Committee.

¹ Quotation of the Options is subject to satisfaction of the ASX Listing Rules criteria. If the ASX Listing Rules criteria is not satisfied the Options will still be issued but will not be tradeable on the market conducted by ASX.

-Ends-

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or febridx.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 411 137 080
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598

Important Notices

This announcement is issued by Lumos Diagnostics Holdings Limited. This announcement is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation, solicitation, advice or recommendation to subscribe for, retain or purchase any entitlements or securities in Lumos Diagnostics Holdings Limited in any jurisdiction. This letter does not constitute financial product advice and does not and will not form any part of any contract for the acquisition of Lumos Diagnostics Holdings Limited ordinary shares.

Not for Distribution or Release in the United States

This letter does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any person in the United States or in any other jurisdiction in which such an offer would be illegal. The New Shares have not been, nor will be, registered under the U.S. Securities Act of 1933 as amended (U.S. Securities Act) or under the securities laws of any state or other jurisdiction of the United States. The New Shares may not be issued to, purchased or traded by, or taken up by, any person in the United States or any person acting for the account or benefit of a person in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

Important Notice to Nominees

Because of legal restrictions, you must not send copies of this letter nor any material relating to the Retail Entitlement Offer to any of your clients (or any other person) acting for the account or benefit of any person in any other jurisdiction outside of Australia and New Zealand. Failure to comply with these restrictions may result in violations of applicable securities laws.